Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Dissolution failure

The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose.

405 FDA drug recalls with this cause, newest first.

These recalls happen when a tablet or capsule does not dissolve the way its specification requires. Because dissolution controls how the drug is released, a failure can mean a patient absorbs it too slowly, too quickly, or not at all - a particular concern for extended-release products, where the release profile is the whole point.

Total recalls
405
Class I (high risk)
9
Currently ongoing
73
Most recent
Sep 3, 2026

Most-cited firms for this cause

  • Dr. Reddy's Laboratories, Inc.48
  • Sun Pharmaceutical Industries INC17
  • Ascend Laboratories, LLC15
  • American Health Packaging14
  • Teva Pharmaceuticals USA11
  • The Harvard Drug Group10
  • Glenmark Pharmaceuticals Inc., USA10
  • Zydus Pharmaceuticals (USA) Inc9
Class III · Low risk

Trokendi XR

Failed dissolution specifications.

Ongoing Dissolution failure Supernus Pharmaceuticals, Inc. NDC 17772-102-30 D-0833-2026
Class II · Moderate risk

Prasugrel HCI

Failed Dissolution Specifications. Notification from the manufacturer that lot is being recalled due to failed dissolution

Ongoing Dissolution failure Golden State Medical Supply Inc. D-0847-2026
Class II · Moderate risk

Prasugrel Tablets

Failed Dissolution Specifications; product failed to meet 18-month stability testing acceptance criteria

Ongoing Dissolution failure Mylan Pharmaceuticals Inc NDC 0378-5186-93 D-0839-2026
Class II · Moderate risk

Paxil CR

Failed Dissolution Specifications; product failed to meet 24-month stability testing acceptance criteria

Ongoing Dissolution failure Apotex Corp. NDC 60505-4379-3 D-0804-2026
Class II · Moderate risk

Diovan (valsartan)

Failed Dissolution Specifications

Ongoing Dissolution failure Novartis Pharmaceuticals Corporation NDC 0078-0359-34 D-0746-2026
Class III · Low risk

Trokendi XR

Failed Dissolution Specifications

Ongoing Dissolution failure Supernus Pharmaceuticals, Inc. NDC 17772-101-30 D-0758-2026
Class II · Moderate risk

GSMS Incorporated

Failed Dissolution Specifications: During 12-month long-term stability testing, subject lot was out of specification (low) for stage 3 dissolution at the 24-hour timepoint.

Ongoing Dissolution failure Golden State Medical Supply Inc. NDC 51407-268-90 D-0587-2026
Class II · Moderate risk

Niacin Extended-release Tablets

Failed Dissolution Specifications: during 12M LT stability testing OOS low for Stage 3 dissolution at the 24-hour timepoint.

Ongoing Dissolution failure Lannett Company Inc. NDC 62175-322-46 D-0584-2026
Class II · Moderate risk

Xanax XR

Failed Dissolution Specifications

Ongoing Dissolution failure Viatris, Inc. NDC 58151-506-91 D-0444-2026
Class II · Moderate risk

Amantadine HCl

Failed Dissolution Specifications: This recall has been initiated due to an Out of Specification finding in dissolution.

Ongoing Dissolution failure AvKARE NDC 50268-069-15 D-0341-2026